Drug Profile
Research programme: targeted cancer diagnostics - Cancer Targeting Technology
Alternative Names: CTT-54Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Cancer Targeted Technology
- Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Prostate-cancer(Diagnosis) in USA (Parenteral)
- 05 Aug 2016 Preclinical development in Prostate cancer is underway in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer(Diagnosis) in USA (Parenteral)